AAN 2016 Seizure Disorders

Verapamil adjuvant therapy showed no benefit versus placebo in patients with refractory epilepsy on standard antiepileptic drug (AED) treatment

Most patients on first-line anti-epileptic drug (AED) monotherapy continue initial treatment for nearly 1.5 years, according to a retrospective database study reported at the 68th AAN Annual Meeting.

Individual neurocognitive treatment-emergent adverse events (TEAEs) appear to be relatively infrequent among patients administered USL255 (Qudexy® XR [topiramate] extended-release capsules) for refractory partial-onset seizures (POS).

Women with >1 eclamptic seizure were more likely to receive an AED, especially if the first seizure occurred postpartum.

Use of lacosamide as the last antiepileptic drug (AED) a patient is administered for status epilepticus (SE) is “strongly associated with termination of status.”

Topiramate may increase risk of developing psychiatric comorbidities in people with epilepsy when compared with valproate, carbamazepine, lamotrigine, and levetiracetam, all of which may lower risk, according to study results reported at the 68th AAN Annual Meeting.

Adjunctive eslicarbazepine acetate (ESL) reduces seizure severity in patients with refractory partial-onset seizures (POS), suggests a post-hoc analysis presented at the 68th AAN Annual Meeting.

Seizure free rates for new investigational anti-epileptic drug (AED), YKP3089, were improved by almost 20% compared to placebo in a randomized trial.

The antiepileptic perampanel has been shown to have similar efficacy across ages and sexes in treating primary generalized tonic-clonic seizures (PGTCS), claims a new study presented at the 68th Annual AAN Meeting.

Long-term adjunctive brivaracetam treatment reduces seizure frequency and sustains seizure freedom, data from a pooled analysis presented at the 68th Annual AAN Meeting have shown.